TORONTO
REFERENCES
1. Gray J. Bill would force drug makers to give customers data on risks. New York Times. July 25, 1996:A11. [Context Link]
2. D'Arcy PF, Griffin JP. Thalidomide revisited. Adverse Drug React Toxicol Rev. 1994;13:65-76. [Medline Link] [Context Link]
3. Cluff LE, Thornton CF, Seidl LG. Studies on the epidemiology of adverse drug reactions, part 1: methods of surveillance. JAMA. 1964;188:976-983. [Context Link]
4. Seidl LG, Thornton GF, Smith JW, Cluff LE. Studies on the epidemiology of adverse drug reactions, III: reactions in patients on a general medical service. Johns Hopkins Hosp Bull. 1966;119:299-315. [Context Link]
5. Borda IT, Slone D, Jick H. Assessment of adverse reactions within a drug surveillance program. JAMA. 1968;205:99-101. [Medline Link] [Context Link]
6. Miller RR. Hospital admissions due to adverse drug reactions: a report from the Boston Collaborative Drug Surveillance Program. Arch Intern Med. 1974;134:219-223. [Medline Link] [Context Link]
7. Smith JW, Seidl LG, Cluff LE. Studies on the epidemiology of adverse drug reactions, V: clinical factors influencing susceptibility. Ann Intern Med. 1966;65:629-640. [Medline Link] [Context Link]
8. World Health Organization. International Drug Monitoring: The Role of the Hospital. Geneva, Switzerland: World Health Organization; 1966. Technical Report Series No. 425. [Context Link]
9. Bates DB, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med. 1993;8:289-294. [Medline Link] [Context Link]
10. Karch FE, Lasagna L. Adverse drug reactions: a critical review. JAMA. 1975;234:1236-1241. [Medline Link] [Context Link]
11. Chalmers TC, Smith H, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981;2:31-49. [Medline Link] [Context Link]
12. Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M, Lasagna L. Adverse drug reactions-a matter of opinion. Int J Clin Pharmacol Ther. 1976;19:489-92. [Context Link]
13. Colditz GA, Burdick E, Mosteller F. Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am J Epidemiol. 1995;142:371-382. [Medline Link] [Context Link]
14. DerSimonian L, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. [Medline Link] [Context Link]
15. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Stat Med. 1995;14:395-411. [Context Link]
16. Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993;27:832-840. [Medline Link] [Context Link]
17. Rosner B. Fundamentals of Biostatistics. 4th ed. New York, NY: Duxbury Press; 1995. [Context Link]
18. Morgan K, Morgan S, Quitno N. Health Care State Rankings 1996. 4th ed. Lawrence, Kan: Morgan Quitno Press; 1996. [Context Link]
19. Bates DW, Boyle DL, Vander Vliet MB, Scheider J, Leape LL. Relationship between medication errors and adverse drug reactions. J Gen Intern Med. 1995;10:199-205. [Medline Link] [Context Link]
20. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995;274:29-34. [Fulltext Link] [Medline Link] [Context Link]
21. Bowman L, Carlstedt BC, Black CD. Incidence of adverse drug reactions in adult medical inpatients. Can J Hosp Pharm. 1994;47:209-216. [Context Link]
22. Steel K, Gertman PM, Crescenzi C, Anderson J. Iatrogenic illness on a general medical service at a university hospital. N Engl J Med. 1981;304:638-642. [Medline Link] [Context Link]
23. Mitchell AA, Goldman P, Shapiro S, Slone S. Drug utilization and reported adverse reactions in hospitalized children. Am J Epidemiol. 1979;110:196-204. [Medline Link] [Context Link]
24. Bennett BS, Lipman AG. Comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse drug reactions. Am J Hosp Pharm. 1977;34:931-936. [Medline Link] [Context Link]
25. May FE, Fuller S, Stewart RB. Drug use and adverse drug reactions prior to and during hospitalization. J Am Pharm Assoc. 1977;17:560-598. [Medline Link] [Context Link]
26. Miller RR. Drug surveillance utilizing epidemiological methods: a report from the Boston Collaborative Drug Surveillance Program. Am J Hosp Pharm. 1973;30:584-592. [Medline Link] [Context Link]
27. McKenzie MW, Stewart RB, Weiss CF, Cluff LE. A pharmacist- based study of the epidemiology of adverse drug reactions in pediatric medicine patients. Am J Hosp Pharm. 1973;30:898-903. [Medline Link] [Context Link]
28. Wang R, Terry LC. Adverse drug reactions in a Veterans Administration hospital. J Clin Pharmacol New Drugs. 1971;11:14-18. [Medline Link] [Context Link]
29. Gardner P, Watson LJ. Adverse drug reactions: a pharmacist-based monitoring system. J Clin Pharm Ther. 1970;11:802-807. [Context Link]
30. Sidel VW, Koch-Weser J, Barnett GO, Eaton A. Drug utilization and adverse reactions in a general hospital. Hospitals. 1967;41:80-88. [Medline Link] [Context Link]
